Prediction of new targets and mechanisms for quercetin in the treatment of pancreatic cancer, colon cancer, and rectal cancer

Pang, Bing; Xu, Xiaoguang; Lü, Yao; Han, Jing; Yang, Rongrong; Jiang, Chunmei; Shao, Dongyan; Liu, Yanlin; Shi, Junling

doi:10.1039/c9fo01168d

Cited by 53 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alone or with gemcitabine, quercetin administered orally in the diet has been reported to inhibit pancreatic cancer. Although the mechanisms have not been elucidated and the results are divergent, CD36 was suggested as a possible target for quercetin because this flavonoid promotes the cell adhesion, regulates the thrombospondin-1 activity, and increases FAs uptake and oxidation by activating glutathione transferases [69].…”

Section: Cd36 Can Regulate Chemoresistance In Pancreatic Cancermentioning

confidence: 99%

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

Tănase

Gheorghișan-Gălățeanu

Popescu

et al. 2020

IJMS

View full text Add to dashboard Cite

Starting from the recent identification of CD36 and CD97 as a novel marker combination of fibroblast quiescence in lung during fibrosis, we aimed to survey the literature in search for facts about the separate (or concomitant) expression of clusters of differentiation CD36 and CD97 in either tumor- or pancreatic-cancer-associated cells. Here, we provide an account of the current knowledge on the diversity of the cellular functions of CD36 and CD97 and explore their potential (common) contributions to key cellular events in oncogenesis or metastasis development. Emphasis is placed on quiescence as an underexplored mechanism and/or potential target in therapy. Furthermore, we discuss intricate signaling mechanisms and networks involving CD36 and CD97 that may regulate different subpopulations of tumor-associated cells, such as cancer-associated fibroblasts, adipocyte-associated fibroblasts, tumor-associated macrophages, or neutrophils, during aggressive pancreatic cancer. The coexistence of quiescence and activated states in cancer-associated cell subtypes during pancreatic cancer should be better documented, in different histological forms. Remodeling of the local microenvironment may also change the balance between growth and dormant state. Taking advantage of the reported data in different other tissue types, we explore the possibility to induce quiescence (similar to that observed in normal cells), as a therapeutic option to delay the currently observed clinical outcome.

show abstract

Section: Cd36 Can Regulate Chemoresistance In Pancreatic Cancermentioning

confidence: 99%

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

Tănase

Gheorghișan-Gălățeanu

Popescu

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Focusing our efforts on CRC, we confirmed AMHRII expression, both at the mRNA level by ISH in most cases (64.7%) and at the protein level using immunoperoxidase (53%) or immunofluorescence. Using flow cytometry on fresh tissues to quantify AMHRII expression at the plasma membrane, we showed that AMHRII is aberrantly expressed in CRC cells as compared to normal colonic epithelial cells in 70% of CRC with a mean receptor density of 50,000, a level even slightly higher than that found in ovarian cancers (39,000). This protein expression is relatively high in comparison to the level of mRNA transcription observed, indicating that post-translational regulation plays a major role in AMHRII expression [32].…”

Section: Discussionmentioning

confidence: 87%

“…Concerning CRC, no role of AMH/AMHRII in colon embryogenesis has been described so far. However, transcription of AMH and AMHRII in colon cancer were mentioned recently [38] and a negative impact of AMH on survival of patients with CRC has been suggested in a recent publication [39] and as well as on the Protein Atlas website (https://www.proteinatlas.org/ENSG00000104899-AMH/pathology accessed on 27 January 2021). We recently confirmed AMH protein expression by IHC in some CRC FFPE samples (Supplementary Figure S3).…”

Section: Discussionmentioning

confidence: 99%

The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer

Barret¹,

André

Jarry

et al. 2021

Biology

View full text Add to dashboard Cite

The anti-Müllerian hormone (AMH) belongs to the TGF-β family and plays a key role during fetal sexual development. Various reports have described the expression of AMH type II receptor (AMHRII) in human gynecological cancers including ovarian tumors. According to qRT-PCR results confirmed by specific In-Situ Hybridization (ISH) experiments, AMHRII mRNA is expressed in an extremely restricted number of normal tissues. By performing ISH on tissue microarray of solid tumor samples AMHRII mRNA was unexpectedly detected in several non-gynecological primary cancers including lung, breast, head and neck, and colorectal cancers. AMHRII protein expression, evaluated by immunohistochemistry (IHC) was detected in approximately 70% of epithelial ovarian cancers. Using the same IHC protocol on more than 900 frozen samples covering 18 different cancer types we detected AMHRII expression in more than 50% of hepato-carcinomas, colorectal, lung, and renal cancer samples. AMHRII expression was not observed in neuroendocrine lung tumor samples nor in non-Hodgkin lymphoma samples. Complementary analyses by immunofluorescence and flow cytometry confirmed the detection of AMHRII on a panel of ovarian and colorectal cancers displaying comparable expression levels with mean values of 39,000 and 50,000 AMHRII receptors per cell, respectively. Overall, our results suggest that this embryonic receptor could be a suitable target for treating AMHRII-expressing tumors with an anti-AMHRII selective agent such as murlentamab, also named 3C23K or GM102. This potential therapeutic intervention was confirmed in vivo by showing antitumor activity of murlentamab against AMHRII-expressing colorectal cancer and hepatocarcinoma Patient-Derived tumor Xenografts (PDX) models.

show abstract

“…Given these findings, one can extrapolate that miR-let7-a expression could be used to assess the efficacy of quercetin against pancreatic cancer. Importantly, bioinformatics tools and database analysis have also been explored to predict the new mechanisms and targets of quercetin in cancer models, including pancreatic cancer [68]. Of various targets, CD36 and thrombospondin-1 were identified to be targeted by quercetin in pancreatic cancer [68].…”

Section: Quercetin and Micrornamentioning

confidence: 99%

“…Importantly, bioinformatics tools and database analysis have also been explored to predict the new mechanisms and targets of quercetin in cancer models, including pancreatic cancer [ 68 ]. Of various targets, CD36 and thrombospondin-1 were identified to be targeted by quercetin in pancreatic cancer [ 68 ].…”

Section: Quercetinmentioning

confidence: 99%

Dietary Polyphenols in Cancer Chemoprevention: Implications in Pancreatic Cancer

et al. 2020

View full text Add to dashboard Cite

Naturally occurring dietary agents present in a wide variety of plant products, are rich sources of phytochemicals possessing medicinal properties, and thus, have been used in folk medicine for ages to treat various ailments. The beneficial effects of such dietary components are frequently attributed to their anti-inflammatory and antioxidant properties, particularly in regards to their antineoplastic activities. As many tumor types exhibit greater oxidative stress levels that are implicated in favoring autonomous cell growth activation, most chemotherapeutic agents can also enhance tumoral oxidative stress levels in part via generating reactive oxygen species (ROS). While ROS-mediated imbalance of the cellular redox potential can provide novel drug targets, as a consequence, this ROS-mediated excessive damage to cellular functions, including oncogenic mutagenesis, has also been implicated in inducing chemoresistance. This remains one of the major challenges in the treatment and management of human malignancies. Antioxidant-enriched natural compounds offer one of the promising approaches in mitigating some of the underlying mechanisms involved in tumorigenesis and metastasis, and therefore, have been extensively explored in cancer chemoprevention. Among various groups of dietary phytochemicals, polyphenols have been extensively explored for their underlying chemopreventive mechanisms in other cancer models. Thus, the current review highlights the significance and mechanisms of some of the highly studied polyphenolic compounds, with greater emphasis on pancreatic cancer chemoprevention.

show abstract

Prediction of new targets and mechanisms for quercetin in the treatment of pancreatic cancer, colon cancer, and rectal cancer

Abstract: Quercetin has been widely found to exhibit anticancer activity with low toxicity and prevalence in foods.

Cited by 53 publications

References 34 publications

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer

Dietary Polyphenols in Cancer Chemoprevention: Implications in Pancreatic Cancer

Contact Info

Product

Resources

About